A feasibility study of the use of saliva as an alternative to leukocytes as a source of DNA for the study of Pt-DNA adducts in cancer patients receiving platinum-based chemotherapy.
This note presents a comparison of the use of saliva versus leukocytes for the determination of Pt-DNA adducts obtained from patients undergoing platinum-based chemotherapy. Samples of both blood and saliva were taken pre- and post-treatment and were analysed via sector-field inductively coupled plasma mass spectrometry (SF-ICP-MS) to determine the level of Pt-DNA adducts formed. As expected, significant inter-patient variability was seen; however, a lack of correlation between the levels of adducts observed in saliva and blood samples was also observed (Pearson correlation coefficient r = -0.2598). A high yield of DNA was obtained from saliva samples, but significant difficulties were experienced in obtaining patient adherence to the saliva sampling procedure. In both leukocyte and saliva samples, not only was Pt from previous chemotherapy cycles detected, but the rapid appearance of Pt in the DNA was noted in both sample types 1 h after treatment.
Centre for Analytical Science, Department of Chemistry, Loughborough University, Loughborough, LE11 3TU, UK.
Sarah E
SE
Taylor
Joanna P
JP
Wood
Anne L
AL
Thomas
George D D
GD
Jones
Helen J
HJ
Reid
Barry L
BL
Sharp
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology*; D018736:DNA Adducts / Q000032:analysis*; D006801:Humans; D007962:Leukocytes / Q000737:chemistry / Q000187:drug effects; D013058:Mass Spectrometry; D009369:Neoplasms / Q000737:chemistry / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin; D010984:Platinum / Q000032:analysis*; D012463:Saliva / Q000737:chemistry* / Q000187:drug effects
D000970:Antineoplastic Agents; D018736:DNA Adducts; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D010984:Platinum; D002945:Cisplatin